

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)


PCT

(10) International Publication Number  
WO 2005/012327 A2

- (51) International Patent Classification<sup>7</sup>: C07H 19/10, A61K 31/7068, 31/7072, A61P 35/00
- (74) Agents: HOWARD, Paul, Nicholas et al.; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).
- (21) International Application Number: PCT/GB2004/003148
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 20 July 2004 (20.07.2004)
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0317009.9 21 July 2003 (21.07.2003) GB
- (71) Applicant (for all designated States except US): UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED [GB/GB]; P.O. Box 497, 30-36 Newport Road, Cardiff CF24 0DE (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): MCGUIGAN, Christopher [GB/GB]; 2 Alfreda Road, Whitchurch, Cardiff CF4 2EH (GB).

[Continued on next page]

(54) Title: CHEMICAL COMPOUNDS



\* p=0.096 vs control; \*\* p=0.094 vs control

(57) Abstract: Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an  $\alpha$ -amino acid moiety. The  $\alpha$ -amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.

WO 2005/012327 A2



**Published:**

— without international search report and to be republished upon receipt of that report


*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## Chemical Compounds

The present invention relates to nucleotide derivatives and their use in the treatment of cancer.

5

Nucleoside analogues such as fluorodeoxyuridine (1), cytarabine (2) and gemcitabine (3) are well established as anticancer agents. They function as inhibitors of DNA synthesis after activation to their 5'-phosphate form.




The free bioactive phosphate forms do not in general represent useful drugs due to their poor membrane permeation. In an effort to circumvent this a number of phosphate pro-drug approaches have been reported [Rosowsky et al, *J. Med. Chem.*, 1982, 25, 171-8; Hong et al, *J. Med. Chem.*, 1985, 28, 171-8; Kodama et al, *Jpn. J. Cancer Res.*, 1989, 80, 679-85; Hong et al, 1979, 22, 1428-32; Ji et al, *J. Med. Chem.*, 1990, 33, 2264-70; Jones et al, *Nucleic Acids Res.*, 1989, 17, 7195-7201; Hunston et al, *J. Med. Chem.*, 1984, 27, 440-4; Lorey et al, *Nucleosides Nucleotides*, 1997, 16, 1307-10; Farquhar et al, *J. Med. Chem.*, 1983, 26, 1153-8; Shuto et al, *Nucleosides Nucleotides*, 1992, 11, 437-46; Le Bec et al, 20 *Tet. Letts.*, 1991, 32, 6553-6; Phelps et al, *J. Med. Chem.*, 1980, 23, 1229-32].

In general the phosphate prodrugs have biological properties and therapeutic activities that are similar to, or somewhat lower than, the parent nucleoside analogue.

25 We have carried out extensive work in this area from an antiviral perspective, largely on dideoxy nucleosides, and have reported a phosphoramidate approach which has been widely adopted for the delivery of bio-active phosphates of antiviral nucleosides.


An example is the phosphoramidate (4) derived from anti-HIV d4T (5).



We observed the effect of variations in the ester [McGuigan et al, AVCC, 1998, 9, 473-9],  
 5 amino acid [McGuigan et al, Antiviral Res., 1997, 35, 195-204; AVCC, 2000, 11, 111-6],  
 and aryl [Siddiqui et al, J. Med. Chem., 1999, 42, 393-9] regions of the phosphoramidate,  
 as well as the effect of amino acid stereochemistry [McGuigan et al, AVCC, 1996, 7, 184-  
 8], phosphate stereochemistry [Allender et al, Analytica Chim. Acta, 2001, 435, 107-13]  
 and nucleoside [Balzarini et al, BBRC, 1996, 225, 363-9; McGuigan et al, BioOrg. Med,  
 10 Chem. Lett., 1996, 6, 2369-62; McGuigan et al, Bioorg. Med. Chem. Lett., 2000, 10, 645-  
 7].

This work has lead to the optimal description of phenyl methoxyalaninyl phosphoramidate  
 as the prototype pro-moiety for the intracellular delivery of bioactive nucleotides  
 15 [Balzarini et al, PNAS, 1996, 93, 7295-9; McGuigan et al, J. Med. Chem., 1996, 39, 1748-  
 53].


Lackey et al [Biochem Pharmacol., 2001, 61, 179-89] have reported the application of our  
 phosphoramidate pro-drug method for antiviral nucleosides to the anti-herpetic agent  
 20 bromovinyl-2'-deoxyuridine (BVDU) (6). In particular, they have found that the phenyl  
 methoxyalaninyl phosphoramidate (7) has significant anti-cancer activity. This is in  
 marked contrast to the parent (antiviral) nucleoside (6).



Limited SAR has been presented by this group, although in their patent applications [WO0239952, EP1200455, CA2317505, US6339151, EP116797, AU2451601] they claim a series of general variations in the base, and phosphate regions. However, based on our  
 5 prior art, the phenyl methoxyalaninyl phosphoramidate (7) would be anticipated to be amongst the most optimal of structures.

Surprisingly, it has now been found that other derivatives of oxyamino acid-phosphoramidate nucleoside analogues are significantly more potent in the treatment of  
 10 cancer than the phenyl methoxyalaninyl phosphoramidate (7).

According to a first aspect of the present invention there is provided a compound of formula I:



15

wherein:

R is selected from the group comprising alkyl, aryl and alkylaryl;

R' and R'' are, independently, selected from the group comprising H, alkyl and alkylaryl, or R' and R'' together form an alkylene chain so as to provide, together with the C atom to

20 which they are attached, a cyclic system;

Q is selected from the group comprising -O- and -CH<sub>2</sub>-;

X and Y are independently selected from the group comprising H, F, Cl, Br, I, OH and methyl (-CH<sub>3</sub>);

Ar is a monocyclic aromatic ring moiety or a fused bicyclic aromatic ring moiety, either of  
 25 which ring moieties is carbocyclic or heterocyclic and is optionally substituted;

Z is selected from the group comprising H, alkyl and halogen; and

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.